Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

A Phase III, Open-Label, Randomised Study of Osimertinib with or without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-Small Cell Lung Cancers (RadiaNCe Lung X)

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer